Celltrion announced on Tuesday that it held a launch event for Omlyclo (omalizumab), its autoimmune disease treatment, in Brazil, Latin America’s largest pharmaceutical market.
The company has hit the ground running, securing government bids in Brazilian states and accelerating its market penetration. This launch event is expected to bolster local healthcare networks and boost Omlyclo’s popularity among medical professionals.
The event drew over 80 attendees, including specialists in allergy, respiratory, and dermatology, as well as insurance representatives. Presentations highlighted Omlyclo’s clinical data, global prescription experiences, and its practical applications in clinical settings.
Through this launch, Celltrion aims to strengthen its ties with influential Brazilian medical professionals, enhance product credibility, and secure support from key local figures, setting the stage for a rapid increase in Omlyclo prescriptions.
Since Omlyclo’s launch last November, Celltrion’s Brazilian subsidiary has maintained robust local marketing efforts. Recently, it achieved a significant milestone by winning a bid from the Santa Catarina state government, securing early supply channels.
Notably, Omlyclo’s first-mover advantage in Brazil is expected to maximize initial market penetration, likely leading to further bidding successes.
Celltrion plans to leverage its existing product sales to expand market share for Omlyclo and other upcoming products in Brazil. The company also aims to broaden its product portfolio across Latin America, cementing its continental market influence.
Kang Kyung-du, Celltrion’s Latin America regional head, stated that the launch event revealed significant interest in Omlyclo among key Brazilian healthcare professionals. Its network with them will be crucial for expanding prescriptions. It is committed to enhancing the bidding success in Brazil and rolling out Omlyclo across Latin America, further solidifying the market position.
